Where investors can find the key to long-term growth
Professional investor David Older of Carmignac highlights three promising companies with large and expanding markets for their products, and a profitable outlook.
Today’s low-growth macroeconomic environment makes it very hard for investors to find growth companies with a profitable outlook. Our approach consists of identifying trends disrupting traditional business models in order to find promising secular, or long-term, growers. We thus develop a multi-thematic portfolio invested across sectors and geographies.
We seek out companies with large and expanding markets for their products and services and an opportunity to penetrate those markets. We are very conscious, however, that most of the available information is already encapsulated in the stock price. We therefore try to develop a view that diverges from the consensus.
Covid-19’s boost to e-commerce
JD.com (Hong Kong: 9618) is one of the leading e-commerce players in China. E-Commerce is a typical example of the disruptive trends we focus on. With the Covid-19 virus and related lockdowns, adoption rates have strongly increased, as people have been reluctant to visit shops.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
However, overall e-commerce penetration rates are still low, especially in developing countries. We are therefore not only invested in the major US players. In China, JD.com has built a reputation around quality, authenticity and delivery.
Furthermore, the company owns all its warehouses and logistical infrastructure. This is a competitive advantage as it ensures a top-quality delivery service while enabling the company to maintain control over its own delivery chain. The upshot has been that JD.com has been able to take significant market share in China during the Covid-19 lockdown period.
Disrupting the payment industry
The Netherlands’ Adyen (Amsterdam: ADYEN) provides a single payment platform to accept payments on mobile phones and at the point of sale. Electronic payments are another example of a disruptive trend where we invest across the value chain. The segment is experiencing significant growth driven by e-commerce and new habits consumers have developed.
Growth is also being driven by measures being taken to avoid the spread of Covid-19; the need to limit physical contact when shopping is leading to greater use of electronic payments. Adyen’s business is centred on a single purpose-built global IT platform, originally only for e-commerce for large global enterprise clients. Its IT platform is now widely considered to be best-in-class in the sector. We also like the fact that the company is owned and managed by the founder himself.
Healthy returns from healthcare
Healthcare is another appealing segment of the market. The industry is ever evolving, while the ageing world population is also fuelling growth. Centene (NYSE: CNC), a managed-care company, provides health insurance in the US. It is the largest player in the market for Medicaid, the US health insurance system that provides a safety net for those on low incomes.
Centene is currently making sure that the newly unemployed still have access to healthcare. Its diversification into the faster-growing Medicare Advantage business (a part of the federal health-insurance programme) and its significant scale enable the company to remain competitive in a rapidly changing market.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
David Older, Carmignac Gestion.
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge
-
Why stagflation now seems like America's "optimistic scenario"
Investors have gone into tariff shock, and stagflation could now be the optimistic scenario for the US economy.
By Alex Rankine
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves